IMUNON Soars 27.71% as it Prepares for Phase III Trial of IL-12 Gene Therapy for Ovarian Cancer

Introduction

IMUNON INC (ticker: IMNN) is a clinical-stage biotechnology company listed on the NASDAQ (exchange code “NAS”). At market close on July 17, 2025, the stock price was USD 0.63, reflecting a 27.71% increase on a trading volume of 9.12 million shares. IMUNON is engaged in the development of proprietary immunology and DNA-based platforms—TheraPlas® and PlaCCine—targeting difficult-to-treat conditions such as ovarian cancer and infectious diseases.

Corporate Structure

Headquartered in Lawrenceville, New Jersey, IMUNON employs between 11 and 50 personnel. Its senior leadership team possesses over 50 years of combined experience in research, innovation, and capital management from various organizations, including Lilly, Biogen, Novavax, Science 37, and Genemedicine. The company’s governance structure emphasizes collaboration across disciplines and partnerships with prominent research institutions.

Immunotherapy by Noah Morgan

Developments and News

• October 23–25, 2023 (Boston, MA): Dr. Khursheed Anwer delivered an oral presentation on a DNA-based vaccine technology independent of a virus or device.
• April 2025 (ASCO 2025): Investigators reported final survival analysis from the OVATION-2 trial, which assessed intraperitoneal IL-12-based immunotherapy in combination with neoadjuvant chemotherapy, indicating improvements in progression-free survival.
• June 2025 (Clinical Leader interview): CEO Stacy Lindborg, Ph.D., discussed the design of an upcoming Phase III trial for GEN-1, an IL-12-based gene therapy for advanced ovarian cancer, with overall survival as the primary endpoint.
• June 2025 (OncLive print edition): Dr. Premal Thaker provided expert commentary on IL-12's potential in the treatment of newly diagnosed ovarian cancer, emphasizing IMUNON’s strategy to localize immune activation at the tumor site.

Financial and Strategic Analysis

As of July 2025, IMUNON’s market capitalization was approximately USD 23 million. The 52-week trading range for the stock was USD 0.37 to USD 3.65. The company reported a trailing twelve-month net loss of USD 17.8 million, with a negative EPS of -1.38. Cash and equivalents amounted to USD 2.9 million, while total debt was reported at 223% of equity. The average daily volume for the past month was around 11 million shares.

IMUNON's strategic focus is on two core platforms:

• TheraPlas®: a plasmid DNA platform for immunotherapies, with GEN-1 currently in Phase II development for ovarian cancer.
• PlaCCine: a nucleic acid vaccine platform, validated through preclinical studies targeting the SARS-CoV-2 virus.

Balancing clinical advancements with capital management will be pivotal as the company progresses toward Phase III milestones and considers potential partnering or licensing discussions.

Market Position and Industry Context

IMUNON operates within the immuno-oncology and nucleic acid vaccine sectors, which have attracted substantial investment in recent years, particularly following the success of mRNA vaccine platforms. Treatment approaches for ovarian cancer have largely remained unchanged for decades; thus, IMUNON's localized IL-12 delivery strategy represents an investigational alternative to systemic cytokine therapies. The PlaCCine platform utilizes synthetic delivery systems that are independent of viral vectors or devices, aligning with broader industry trends toward diverse vaccine modalities.

The competitive landscape includes established immuno-oncology companies and gene therapy developers. While challenges exist, IMUNON’s dual-platform strategy and focused pipeline may offer potential differentiation. Continued data generation, regulatory engagement, and collaborations with academic institutions will influence the company’s market positioning.

tl;dr

IMUNON’s stock increased by 27.71% to USD 0.63 on July 17, 2025, as the company prepares to initiate a Phase III trial for the IL-12-based gene therapy GEN-1 targeting ovarian cancer. The company currently holds USD 2.9 million in cash against a net loss of USD 17.8 million (TTM) and has a debt-to-equity ratio of 223%. Key milestones include the ASCO 2025 survival data from the OVATION-2 trial and a trial design that emphasizes overall survival. Upcoming data readouts and potential financing or partnerships will be critical for advancing the pipeline and maintaining financial stability.